Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure

Lapp, Harald, Mitrovic, Veselin, Franz, Norbert, Heuer, Hubertus, Buerke, Michael, Wolfertz, Judith, Mueck, Wolfgang, Unger, Sigrun, Wensing, Georg, Frey, Reiner·2009·Circulation
DOI 10.1161/circulationaha.108.800292

Cited by (148)

Items 101–148 of 148

  1. Diagnosis and individual treatment of cardiovascular diseases: targeting vascular oxidative stress
    Melanie E. Armitage, Mylinh La, Harald H.H.W. Schmidt, Kirstin Wingler · 2010 · Expert Review of Clinical Pharmacology
  2. Cyclic guanosine monophosphate and 10-year change in left ventricular mass: the Multi-Ethnic Study of Atherosclerosis (MESA)
    Vinita Subramanya, Di Zhao, Pamela Ouyang, Wendy Ying, Dhananjay M. Vaidya, Chiadi E. Ndumele, João A.C. Lima, Eliseo Güallar, Ron Cornelis Hoogeveen, Sanjiv Jayendra Shah et al. · 2021 · Biomarkers
  3. Chemie und Biologie der Stimulatoren und Aktivatoren der löslichen Guanylatcyclase
    Markus Follmann, Nils Griebenow, Michael G. Hahn, Ingo Volker Hartung, Franz‐Josef Mais, Joachim Mittendorf, Martina Schäfer, Hartmut Schirok, Johannes‐Peter Stasch, Friederike Stoll et al. · 2013 · Angewandte Chemie
  4. Future and Novel Compounds in the Treatment of Diabetic Nephropathy
    Nienke M. A. Idzerda, Michelle J. Pena, Dick de Zeeuw, Hiddo J.L. Heerspink · 2018 · Springer eBooks
  5. Pharmacological activation of soluble guanylate cyclase improves vascular graft function
    Gábor Veres, Yang Bai, Klára Aliz Stark, Harald Schmidt, Tamás Radovits, Sivakkanan Loganathan, Sevil Korkmaz‐Icöz, Gabor B. Szabo · 2020 · Interactive Cardiovascular and Thoracic Surgery
  6. Emerging drugs for the treatment of bladder storage dysfunction
    Karl‐Erik Andersson · 2022 · Expert Opinion on Emerging Drugs
  7. Assessment of the Effects of Renal Impairment on the Pharmacokinetics of the Soluble Guanylate Cyclase Activator Cinaciguat After a Single Intravenous Dose
    John Lettieri, Christian Scheerans, Martin Blunck, Arthur L. Mazzu, Reiner Frey, Wolfgang M. Mück, Pavur R. Sundaresan · 2011 · The Journal of Clinical Pharmacology
  8. Regulation and Physiological Functions of NO-Sensitive Guanylyl Cyclase
    Doris Koesling, Michael Russwurm, Evanthia Mergia · 2017 · Elsevier eBooks
  9. Soluble guanylate cyclase modulators—a novel therapeutic approach for diabetic kidney disease
    Yiyue Xu, Xuan Wu, Mingpai Ge, Kunhan Liang, Jixin Xing, Peng Zhang, Huilin LI, Zhiyong Guo, Xiaobin Mei · 2025 · Renal Failure
  10. Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy
    Mihály Ruppert, Sevil Korkmaz‐Icöz, Shiliang Li, Paige Brlecic, Balázs Tamás Németh, Attila Oláh, Eszter Maria Horvath, Gábor Veres, Sven T. Pleger, Niels Grabe et al. · 2019 · Frontiers in Physiology
  11. Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activation
    Theresa Wittrien, Anne Rühle, Christin Elgert, Ilka Mathar, Peter Sandner, Sönke Behrends · 2025 · Biochemical Pharmacology
  12. Drug therapy for erectile dysfunction
    Francisco Garcia, Eric Chung, Gerald B Brock · 2016 · Wiley eBooks
  13. Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods
    Bing Yan, Jing Zhang, Jun Wang, Hong Yuan · 2025 · Frontiers in Pharmacology
  14. Different sensitivities of porcine coronary arteries and veins to BAY 60–2770, a soluble guanylate cyclase activator
    Masashi Tawa, Keisuke Nakagawa, Mamoru Ohkita · 2024 · Journal of Pharmacological Sciences
  15. Vericiguat, a Soluble Guanylate Cyclase Stimulator Approved for Heart Failure Treatment
    Mohammed Kallash, William H. Frishman · 2025 · Cardiology in Review
  16. Modulating cGMP levels as therapeutic drug targets in cardiovascular and non-cardiovascular diseases
    FZ Mónica, Ferid Murad, Ka Bian · 2014
  17. Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock
    Nils Kronas, Birte Peters, Hans Peter Richter, Alwin Eduard Goetz, Jens Christian Kubitz · 2017 · Experimental and Therapeutic Medicine
  18. Soluble Guanylate Cyclase Modulators in Heart Failure
    Veselin L. Mitrović, Stefan Lehinant · 2012 · InTech eBooks
  19. Nitric oxide pathway: Emerging therapeutic strategies for MASLD
    Yanling Zhang, 张颖, Hongjin Chen, Fangfang Qi · 2026 · Pathology - Research and Practice
  20. Soluble guanylate cyclase: a potential therapeutic target for heart
    Johannes-Peter StaschJaved Butler · 2013
  21. Moderne Arzneitherapie in der kardiovaskulären Intensivmedizin
    Henning Lemm, S. Dietz, Matthias Janusch, Michael Buerke · 2015 · Der Internist
  22. Renal effects of vasodilators in acute heart failure
    Mattia A. E. Valente, Adriaan A. Voors · 2013 · World Journal of Cardiovascular Diseases
  23. Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation
    Kurt Schmidt, Ernst R. Werner, Bernd Mayer · 2013 · Pteridines
  24. Endothelial dysfunction: basis for many local and systemic conditions
    Thomas F. Münzel, Omar Hahad, Andreas Daiber · 2022 · Elsevier eBooks
  25. Molecular model of soluble guanylyl cyclase: Insight into allostery in nitric oxide signaling
    Bradley G. Fritz · 2011 · UA Campus Repository (The University of Arizona)
  26. Efeito da reposição de insulina nas alterações funcionais e morfológicas do corpo cavernoso, no diabetes induzido por estreptozotocina em camundongos
    Fernanda Del Grossi Ferraz Carvalho · 2012
  27. Endothelial cell function from a tissue engineering perspective
    Irma L. Geenen · 2014 · Research Publications (Maastricht University)
  28. Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
    Christian Scheerans, Martin Blunck, Wolfgang Mueck, Reiner Frey · 2011 · BMC Pharmacology
  29. SOLUBLE GUANYLYL CYCLASE MODULATES REDOX- DEPENDENT REGULATION OF THE CARDIAC SODIUM POTASSIUM PUMP
    Karin K.M. Chia · 2013 · The Sydney eScholarship Repository (The University of Sydney)
  30. The Evolution of Clinical Development: From Technical Success to Clinical Value Creation
    Markus Hinder, Alexander Schuhmacher · 2016 · Wiley eBooks
  31. The nitric oxide and cyclic guanosine monophosphate pathway
    Colin Church, Andrew J. Peacock · 2011 · CRC Press eBooks
  32. Alterations in Renal Function in Heart Failure
    Guido Boerrigter, Lisa C. Costello‐Boerrigter, John C. Jr Burnett · 2010 · Elsevier eBooks
  33. Severe Heart Failure
    Eduard Shantsila, Benjamin Wrigley, Michael D. Sosin, Gregory Y.H. Lip · 2011 · Elsevier eBooks
  34. Moduladores alostéricos da enzima guanilato ciclase na terapia anti-plaquetária: estudos in vitro, ex vivo e in vivo.
    Plinio Ferreira · 2017 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  35. Authors reply to “No, we are not—we keep forgetting the right ventricle”
    Luxitaa Goenka, Melvin George, Sandhiya Selvarajan · 2017 · European Journal of Clinical Pharmacology
  36. A szolubilis guanilát-cikláz aktivátor cinaciguat megelőzi a kardiális diszfunkció kialakulását 1-es típusú cukorbetegség patkánymodelljében
    Csaba Mátyás, Bálint András Barta, Balázs Tamás Németh, Attila Oláh, László Hidi, Ede Birtalan, Dalma Kellermayer, Mihály Ruppert, Sevil Korkmaz‐Icöz, Gábor Kökény et al. · 2017 · Cardiologia Hungarica
  37. Chronic kidney disease and congestive heart failure management: cardionephrologist's role
    Rodolfo Fernando Rivera, Fulvio Floccari, Luca Di Lullo, Antonio Raffaele Michele Granata, Francesco Logias, Alessandro D’Amelio, Fulvio Fiorini, V. Sala, Annalisa Villani, Moreno Malaguti et al. · 2012 · Giornale di Techniche Nefrologiche e Dialitiche
  38. Stimulators and activators of soluble guanylate cyclase: potential therapeutic indications
    Bobby D. Nossaman, George F. Lasker, Edward A. Pankey, Raj Parikh, Philip J. Kadowitz · 2013
  39. CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2
    Vladimir O. Popov, N. A. Bulanov, Г. Г. Иванов · 2012 · Rational Pharmacotherapy in Cardiology
  40. Observations concerning the mechanism of action of glyceryl trinitrate
    Kangbin Zhou · 2018 · TSpace (University of Toronto)
  41. Organic and dietary nitrates, inorganic nitrite, nitric oxide donors, and soluble guanylate cyclase stimulation
    Kevin O’Gallagher, Andrew James Webb · 2022 · Elsevier eBooks
  42. 心不全研究の進歩(循環器学2010年の進歩)
    原口 剛, 磯部 光章 · 2011 · Journal of JCS Cardiologists
  43. Circulation Editors' Picks
    The Editors · 2011 · Circulation
  44. Akute Herzinsuffizienz
    Uwe Janssens · 2013 · Springer eBooks
  45. Vasodilators
    Susan E. Piper, Theresa A. McDonagh · 2022
  46. Neue Therapiekonzepte bei akut dekompensierter Herzinsuffizienz
    Stefan Lehinant, Veselin L. Mitrović · 2009 · Intensivmedizin und Notfallmedizin
  47. Additional file 1 of Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
    Eva Becker‐Pelster, Michael G. Hahn, Martina Delbeck, Lisa Dietz, Jörg Hüser, Johannes Kopf, Kraemer, Thomas, Tobias Marquardt, Thomas Mondritzki, Johannes Nagelschmitz et al. · 2022 · Figshare
  48. Soluble guanylate cyclase modulation in heart failure and chronic kidney disease: mechanisms, clinical evidence, and translational boundaries
    Wenhui Yuan, Bo Zhou, Changqing Yu · 2026 · Frontiers in Pharmacology